Clinical trial · Interventional
Radical Prostatectomy and Perioperative Fluid Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The optimal amount of fluid a patient need under surgery is not clear. Both to much and to little fluid can damage the organ functions. A strategy called "Goal directed therapy", where the fluid amount a patient need is guided by the stroke volume, has shown to minimize post-operative nausea and vomiting. The investigators intend to investigate if patients treated after these standards, has a better outcome then patients treated after normal regimes, regarding post-operative orthostatic-intolerance.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Maximization of cardiac stroke volume with fluid infusion | Procedure | — | UNRESOLVED |
| Standard therapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Standard treatment
- interventionNames
- Procedure: Standard therapy
- type
- ACTIVE_COMPARATOR
- label
- SV maximization
- interventionNames
- Procedure: Maximization of cardiac stroke volume with fluid infusion
Primary outcomes (1)
- measure
- To investigate orthostatic cardiovascular response and orthostatic intolerance in patients after removal of the prostate
- timeFrame
- 6 hours
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with cancer in there prostate Exclusion Criteria: * Patients who don't understand the information * ASA \> III * Patients that are under treatment with the drug triazolam * Patients with af known renal decease * Patients with a psychiatric decease * Alcohol abuse * Severe haemorrhagic decease * Cancer in the mouth,pharynx, larynx or oesophagus
References
Publications (0)
Data not yet available